STUDY: FIRST TIME STROKE SURVIVORS HAVE SUBSTANTIAL IMMEDIATE AND ACCELERATED LONG TERM-COGNITIVE DECLINE New evidence points to vascular risk factors exerting impact on cognitive function years before stroke onset
SEGMENT
Filmed in Sydney | January 2025
New evidence from the Centre for Healthy Brain Ageing (CHeBA) indicates that older adults who experience a stroke for the first time will have substantial immediate and accelerated long term-cognitive decline.
Stroke is a leading cause of disability and dementia globally, with projections indicating a continued rise in both prevalence and burden. The new research, published in October 2024 in JAMA Network Open, looked at finding out exactly how a stroke impacts a person’s cognitive abilities.
Stroke occurs when blood flow to part of the brain is blocked or reduced, causing damage to brain cells. Previous research from the Centre has shown that more than a third of stroke survivors’ ability to think, remember and make decisions is significantly disadvantaged after stroke, with clear deficits in cognition or vascular dementia present.
Vascular dementia, the second most common type of dementia, is caused by reduced blood flow to the brain. The research, led by biostatistician and Research Associate Jess Lo, addressed many unanswered questions about this dementia type, which is yet to be studied as extensively as Alzheimer’s disease.
“Although we do experience changes to our brain functioning over time and as we age, certain medical conditions can potentially speed up these changes, which may lead to cognitive impairment or dementia,” says Lo.
The research analysed data from 14 studies that followed community dwelling older adults without a history of stroke or dementia, with an average age of 73 over many years, tracking their health and cognitive abilities. The studies, part of the CHeBA-led international Cohort Studies of Memory in an International Consortium (COSMIC), span 11 countries including Australia, Brazil, France and the US.
With data from 20,860 participants, the researchers identified people who experienced their first stroke during the study period.
The research also found that individuals who had a history of diabetes, hypertension, high cholesterol, cardiovascular disease, depression, smoked or were APOE4 carriers exhibited significantly faster cognitive decline before any stroke.
Senior author on the paper and Co-Director of the Centre for Healthy Brain Ageing (CHeBA), Professor Perminder Sachdev, said that this global collaborative study highlights the significant and lasting negative impact of stroke on brain cognition.
“Our findings can help clinicians better plan for the ongoing needs of stroke survivors who are at risk of disability and a lower quality of life,” said Professor Sachdev.
You Might also like
-
Taiwanese health and research delegation visit Paratus clinical trial site in Canberra
In late August 2025, a Taiwanese delegation comprising government officials from the Taiwanese FDA, various governmental groups, and physicians and researchers from across Taiwan, visited Paratus Clinical’s trial site in Canberra. Their objective was to explore both the differences and similarities between the clinical research ecosystems of Taiwan and Australia.
-
Artificial Intelligence (AI) in clinical trials and clinical care
Australian Health Journal today continues a major episode release on Technology Aided Healthcare Delivery, with part 2 on Artificial Intelligence in trials and clinical care. Interviews were captured at AI, Machine Learning & Robotics in Health conference in October organised by Informa Australia.
-
Specialist physiotherapist successfully mixes online & in-person
Dr. Kieran Richardson (FACP) is a Specialist Physiotherapist, conferred by the Australian College of Physiotherapists (Australian Physiotherapy Association) in 2016. Dr Richardson is the Director of Global Specialist Physiotherapy, a consultancy company providing online Formal Mentoring and Professional Development individual clinicians, clinics, and groups, as well as Second Opinions to clinicians and directly to patients all around the world.